CytomX Therapeutics, Inc.
CTMX
$3.79
-$0.09-2.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -88.88% | -68.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -88.88% | -68.04% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -88.88% | -68.04% | |||
| SG&A Expenses | -2.60% | -2.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.70% | 8.96% | |||
| Operating Income | -59.39% | -1,126.13% | |||
| Income Before Tax | -86.69% | -15,472.53% | |||
| Income Tax Expenses | -6.90% | -7.94% | |||
| Earnings from Continuing Operations | -86.31% | -9,139.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -86.31% | -9,139.61% | |||
| EBIT | -59.39% | -1,126.13% | |||
| EBITDA | -57.49% | -1,564.96% | |||
| EPS Basic | -101.74% | -7,083.33% | |||
| Normalized Basic EPS | -62.20% | -13,325.00% | |||
| EPS Diluted | -94.56% | -7,400.00% | |||
| Normalized Diluted EPS | -62.20% | -13,325.00% | |||
| Average Basic Shares Outstanding | 2.84% | 27.84% | |||
| Average Diluted Shares Outstanding | 2.84% | 27.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||